|
EQS-News: CompuGroup Medical SE & Co. KGaA
/ Key word(s): Financing/Issue of Debt
CompuGroup Medical successfully places Schuldschein of EUR 300 million
CompuGroup Medical SE & Co. KGaA (CGM), one of the world's leading e-health providers, has successfully placed Schuldschein tranches with a total volume of EUR 300 million. The transaction was the Koblenz-based company's debut in the international debt capital market, in addition to traditional bank financing. The emission consists of three tranches with maturities of three, five and seven years. The three-year tranche has a variable interest rate, while the other tranches were issued with fixed and variable interest rates. Originally, an issue volume of EUR 200 million was planned, but this was significantly increased due to strong demand from Germany and abroad at attractive terms. With the funds from the Schuldschein and a simultaneous new issue of a 5-year term loan, the credit facility expiring at the end of January 2025 will be repaid early and the total financing volume will be increased to EUR 1.4 billion with significantly extended maturities. CEO Michael Rauch says: "We are pleased to have met with such a positive response from Schuldschein investors. In addition to traditional bank financing, this gives us access to new sources of financing at attractive conditions and significantly improved maturities. With our strong free cash flow profile and increasing earnings power, we are reducing our leverage and are well equipped to further support our customers in the digitization of healthcare."
CompuGroup Medical is one of the leading e-health companies in the world. With a revenue base of EUR 1.130 billion in 2022, its software products are designed to support all medical and organizational activities in doctors’ offices, pharmacies, laboratories, hospitals and social welfare institutions. Its information services for all parties involved in the healthcare system and its web-based personal health records contribute towards safer and more efficient healthcare. CompuGroup Medical’s services are based on a unique customer base of more than 1.6 million users, including doctors, dentists, pharmacists and other healthcare professionals in inpatient and outpatient facilities. With locations in 21 countries and products in 60 countries worldwide, CompuGroup Medical is the e-health company with one of the highest coverages among healthcare professionals. More than 9,200 highly qualified employees support customers with innovative solutions for the steadily growing demands of the healthcare system.
16.10.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | CompuGroup Medical SE & Co. KGaA |
| Maria Trost 21 | |
| 56070 Koblenz | |
| Germany | |
| Phone: | +49 (0)160 3630362 |
| Fax: | +49 (0)261 8000 3200 |
| E-mail: | investor@cgm.com |
| Internet: | www.cgm.com |
| ISIN: | DE000A288904 |
| WKN: | A28890 |
| Indices: | SDAX, TecDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1749629 |
| End of News | EQS News Service |
|
|
1749629 16.10.2023 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
